Sermorelin is the 1-29 fragment of GHRH that tells the pituitary to release the body's own growth hormone — here is what the studies actually establish.

Start here

Sermorelin is a small synthetic peptide — a 29-amino-acid copy of the first part of a natural brain hormone called GHRH (growth hormone-releasing hormone, the signal your brain sends to release growth hormone). Instead of giving you growth hormone directly, sermorelin nudges your own pituitary gland (a pea-sized gland under the brain) to make and release its own ^[1]. That is the whole pitch: work with the body's own dial rather than overriding it.

What is actually proven? In growth-hormone-deficient children, daily injections roughly doubled how fast they grew ^[1]. In healthy older men, two weeks of injections raised growth hormone and IGF-1 (a hormone the liver makes in response, which carries out many of GH's effects) back toward young-adult levels ^[2]. The honest gaps: long-term adult "anti-aging" safety and benefit are thin, and the flashier wound-healing and cancer signals are still animal or computer studies, not human trials ^[9][8]. What people report, and where to be careful, is on the effects page.

01. What the strongest sermorelin studies measured

The cleanest sermorelin result is pediatric. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous (under-the-skin) GHRH(1-29) accelerated linear growth: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation ^[1]. That is a real, replicated, drug-grade outcome — and it is the foundation under everything else.

The adult data are smaller but consistent on the mechanism. In healthy older men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour growth hormone and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose ^[2]. The pharmacology backs this up: in 30 healthy men, intravenous GHRH(1-29)NH2 triggered GH release at doses as low as 0.25 mcg/kg, peaking at 1-2 mcg/kg, and GH stayed elevated for about three hours even though the peptide itself cleared the blood quickly ^[3].

So the secretagogue works. The skeptical question this site keeps asking is the next one: does "raises GH for a few weeks" translate into the durable adult benefits the marketing promises? On that, the evidence thins fast — and that thinning is the story, not a footnote.

02. Why the mechanism matters for the safety argument

Sermorelin acts upstream. It binds the GHRH receptor on pituitary cells called somatotrophs and switches on the cAMP/PKA pathway (an internal cellular signaling relay) to make the gland release its own GH ^[6]. Because it works through your own gland, the body's brakes stay attached: somatostatin (the off-switch hormone) and IGF-1 negative feedback keep the GH release pulsatile (in bursts) rather than a flat, artificially high level ^[4][12]. An editorial argues that this physiologic, feedback-preserving approach may be gentler than injecting recombinant growth hormone directly ^[4].

That is a genuine mechanistic advantage — and also exactly the kind of claim that gets oversold. "Preserves feedback" is a plausible safety argument, not a proven long-term outcome. No trial has shown that sermorelin avoids the theoretical risks that come with chronically raising GH and IGF-1, both of which are mitogenic (growth-promoting) hormones. This site treats that distinction as load-bearing.

03. The frontier signals — graded, not hyped

The reason this domain leads with a skeptic's lens is the regenerative-oncology-frontier literature, which marketing routinely flattens into "sermorelin heals tissue and fights cancer." The actual evidence is interesting and early. GHRH agonist analogs (laboratory cousins MR-409 and MR-502) promoted wound healing by driving human skin-cell proliferation through the ERK and AKT pathways, and topical MR-409 sped wound closure in animals ^[8]. A GHRH agonist improved outcomes in a mouse model of heart failure ^[10], and a related study targeted the GHRH receptor for cardiac repair after a heart attack ^[11].

The oncology headline is the one to read most carefully. A transcriptomic drug-screening study of 1,018 glioma patients flagged recurrent glioma as the tumor type most "sensitive" to sermorelin in silico — a computer-model prediction, not a clinical trial of sermorelin in cancer ^[9]. It is hypothesis-generating. Reading it as evidence that sermorelin treats cancer is precisely the leap this site exists to flag. A 2025 Nature Reviews Endocrinology synthesis covers this whole GHRH-analog landscape and keeps the agonist-versus-antagonist and preclinical-versus-clinical lines clear ^[6]. The sermorelin results page grades each of these signals by the kind of study behind it.

04. The status that gets misstated most often

Sermorelin was an approved drug. It was FDA-approved (NDA 020443) for diagnosing and treating growth-hormone deficiency in children and was withdrawn from the US market in 2008 for commercial reasons — not because of a safety or efficacy problem ^[1]. It is now prepared by compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under the FDA's interim Section 503A policy (final guidance January 2025), which means the agency does not intend enforcement action against that compounding. That status should not be conflated with other GH-axis peptides reviewed by the Pharmacy Compounding Advisory Committee in October 2024 — sermorelin's situation is distinct.

Two more facts the due-diligence reader should carry: GH secretagogues, including GHRH analogs, are prohibited in sport by WADA (class S2), with detection methods in place; and the cautious consensus on adult anti-aging use is best summarized by an Annals of Internal Medicine editorial that called it "not yet ready for prime time" ^[5]. This is research-context information, not medical guidance — see the sermorelin benefits page for what the studies do and do not support.